Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 663.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,345 shares of the biopharmaceutical company’s stock after buying an additional 4,645 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $4,694,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Fortitude Family Office LLC bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth $31,000. MCF Advisors LLC increased its position in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares during the period. Criterion Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $37,000. Finally, Bruce G. Allen Investments LLC bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $40,000. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on REGN shares. Bank of America upped their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. BMO Capital Markets increased their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Barclays boosted their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Truist Financial reiterated a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Finally, StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $981.71.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $957.00 on Monday. The stock has a 50-day simple moving average of $943.75 and a 200 day simple moving average of $897.24. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33. The stock has a market capitalization of $105.04 billion, a PE ratio of 28.27, a P/E/G ratio of 2.74 and a beta of 0.17. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The company had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same period in the previous year, the company earned $10.96 earnings per share. The company’s quarterly revenue was up .6% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Joseph J. Larosa sold 1,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $950.00, for a total value of $950,000.00. Following the sale, the executive vice president now owns 38,543 shares of the company’s stock, valued at approximately $36,615,850. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold a total of 9,095 shares of company stock valued at $8,729,766 in the last ninety days. Company insiders own 8.83% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.